Literature DB >> 17487450

Efficacy of intravenous immunoglobulin treatment in lupus erythematosus chorea.

I Lazurova1, Z Macejova2, K Benhatchi2, M Oetterová2, E Antolová3, R A Asherson4, J Rovensky5.   

Abstract

Chorea is a rare complication of systemic lupus erythematosus (SLE) and is strongly related to the presence of antiphospholipid antibodies. Various infections may also be triggering factors in the development of choreiform movements. Additionally, Salmonella infection is the most common opportunistic bacterial infection in SLE patients. We report a case of a 33-year-old woman with SLE who developed lupus erythematosus-associated chorea with multiple involuntary movements and cognitive disturbances. Because the methylprednisolone therapy administered appeared to lead to Salmonella enteritidis infection, intravenous immunoglobulin (IVIg) in a total dose 100 g was administered after which a remarkable improvement of the abnormal movements and cognitive function was noted. Within 7 days, the patient had returned to normal. We therefore conclude that IVIg therapy may be an effective therapeutic approach for the treatment of the acute cerebral complications of SLE, especially in cases in whom other therapeutic strategies are ineffective or harmful.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17487450     DOI: 10.1007/s10067-007-0627-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  16 in total

1.  A patient with systemic lupus erythematosus and Salmonella enteritidis bacteraemia complicated by rhabdomyolysis and acute cholecystitis.

Authors:  A A Blaauw; T J Tobé; R W Derksen; J W Bijlsma
Journal:  Rheumatology (Oxford)       Date:  2000-01       Impact factor: 7.580

2.  Nonthrombotic manifestations of the antiphospholipid syndrome: away from thrombosis?

Authors:  Ronald A Asherson; Ricard Cervera; Daniel Shepshelovich; Yehuda Shoenfeld
Journal:  J Rheumatol       Date:  2006-06       Impact factor: 4.666

3.  [Systemic lupus erythematosus presenting with a choreo-athetosic syndrome associated with antiphospholipid antibodies].

Authors:  M A Rafai; B El Moutawakil; I Gam; K Hakim; H Fadel; N Kissani; I Slassi
Journal:  Rev Neurol (Paris)       Date:  2005-10       Impact factor: 2.607

4.  Churg-Strauss syndrome and pregnancy: successful treatment with intravenous immunoglobulin.

Authors:  Samara Amaris Rutberg; David E Ward; Bernard J Roth
Journal:  J Clin Rheumatol       Date:  2002-06       Impact factor: 3.517

5.  Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin.

Authors:  Y Sherer; Y Levy; P Langevitz; M Lorber; F Fabrizzi; Y Shoenfeld
Journal:  Clin Rheumatol       Date:  1999       Impact factor: 2.980

Review 6.  Intravenous immunoglobulin treatment in vasculitis and connective tissue disorders.

Authors:  Andreas Steinbrecher; Peter Berlit
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

7.  Neuropsychiatric syndromes in lupus: prevalence using standardized definitions.

Authors:  R L Brey; S L Holliday; A R Saklad; M G Navarrete; D Hermosillo-Romo; C L Stallworth; C R Valdez; A Escalante; I del Rincón; G Gronseth; C B Rhine; P Padilla; D McGlasson
Journal:  Neurology       Date:  2002-04-23       Impact factor: 9.910

8.  Recurrent bacteraemia caused by different Salmonella species in a systemic lupus erythematosus patient.

Authors:  Teresa K F Wang; Pak-Leung Ho; Samson S Y Wong
Journal:  New Microbiol       Date:  2005-04       Impact factor: 2.479

9.  Infections in systemic lupus erythematosus.

Authors:  H M Oh; H H Chng; M L Boey; P H Feng
Journal:  Singapore Med J       Date:  1993-10       Impact factor: 1.858

10.  Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin.

Authors:  Y Tomer; Y Shoenfeld
Journal:  Clin Exp Rheumatol       Date:  1992 Jul-Aug       Impact factor: 4.473

View more
  9 in total

Review 1.  Current and novel therapeutics in the treatment of systemic lupus erythematosus.

Authors:  Cagri Yildirim-Toruner; Betty Diamond
Journal:  J Allergy Clin Immunol       Date:  2011-02       Impact factor: 10.793

2.  Hemichorea with antiphospholipid antibodies in a patient with systemic lupus erythematosus.

Authors:  Ana Vide Brochado; Sofia Pimenta; Marta Silva; Raquel Sousa; Maria Manuel Campos; Iva Brito
Journal:  BMJ Case Rep       Date:  2009-08-19

Review 3.  Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome.

Authors:  José Fidel Baizabal-Carvallo; Cecilia Bonnet; Joseph Jankovic
Journal:  J Neural Transm (Vienna)       Date:  2013-04-13       Impact factor: 3.575

Review 4.  The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data.

Authors:  Giovanna Vitaliti; Omidreza Tabatabaie; Nassim Matin; Caterina Ledda; Piero Pavone; Riccardo Lubrano; Agostino Serra; Paola Di Mauro; Salvatore Cocuzza; Raffaele Falsaperla
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 5.  Pragmatic approaches to therapy for systemic lupus erythematosus.

Authors:  Wen Xiong; Robert G Lahita
Journal:  Nat Rev Rheumatol       Date:  2013-10-29       Impact factor: 20.543

Review 6.  Autoimmune and Paraneoplastic Chorea: A Review of the Literature.

Authors:  Kevin Kyle; Yvette Bordelon; Nagagopal Venna; Jenny Linnoila
Journal:  Front Neurol       Date:  2022-03-18       Impact factor: 4.003

7.  Antiphospholipid-related chorea.

Authors:  Silvio Peluso; Antonella Antenora; Anna De Rosa; Alessandro Roca; Gennaro Maddaluno; Vincenzo Brescia Morra; Giuseppe De Michele
Journal:  Front Neurol       Date:  2012-10-22       Impact factor: 4.003

Review 8.  Revisiting the molecular mechanism of neurological manifestations in antiphospholipid syndrome: beyond vascular damage.

Authors:  M Carecchio; R Cantello; C Comi
Journal:  J Immunol Res       Date:  2014-03-13       Impact factor: 4.818

Review 9.  Treatment of Secondary Chorea: A Review of the Current Literature.

Authors:  Erin Feinstein; Ruth Walker
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2020-07-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.